Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Lahey Clinic |
---|---|
Information provided by: | Lahey Clinic |
ClinicalTrials.gov Identifier: | NCT00532571 |
To compare the efficacy, safety and tolerability of Coenzyme Q 10 versus placebo in patients with atypical parkinsonian syndromes corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP) ).
Condition | Intervention | Phase |
---|---|---|
Progressive Supranuclear Palsy Neurological Disorders |
Drug: CoQ10 |
Phase II Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Safety/Efficacy Study |
Official Title: | Effects of Coenzyme Q10 in PSP and CBD, A Randomized, Placebo-Controlled, Double Blind Cross Over Pilot Study |
Ages Eligible for Study: | 40 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | CoQ10 with PSP/CBD |
Study First Received: | September 18, 2007 |
Last Updated: | September 19, 2007 |
ClinicalTrials.gov Identifier: | NCT00532571 History of Changes |
Health Authority: | United States: Institutional Review Board |
CoQ10 PSP CBD |
Ganglion Cysts Eye Diseases Basal Ganglia Diseases Central Nervous System Diseases Trace Elements Brain Diseases Neurodegenerative Diseases Coenzyme Q10 Paralysis Ocular Motility Disorders |
Signs and Symptoms Movement Disorders Vitamins Ubiquinone Supranuclear Palsy, Progressive Neurologic Manifestations Progressive Supranuclear Palsy Micronutrients Motor Neuro-ophthalmic Disorders |
Growth Substances Eye Diseases Physiological Effects of Drugs Nervous System Diseases Basal Ganglia Diseases Central Nervous System Diseases Brain Diseases Ophthalmoplegia Neurodegenerative Diseases Pharmacologic Actions Coenzyme Q10 |
Paralysis Signs and Symptoms Ocular Motility Disorders Movement Disorders Vitamins Supranuclear Palsy, Progressive Neurologic Manifestations Micronutrients Cranial Nerve Diseases Tauopathies |